ArticleClinical and experimental nephrology2026
Predictions of cisplatin-induced hyponatremia in patients with malignancy: a retrospective cohort survey of all cisplatin administration in clinical practice.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the rise of cancer immunotherapy, cisplatin remains a cornerstone in chemotherapy. Hyponatremia is a common but under-recognized adverse event of cisplatin. Previous studies on cisplatin-induced hyponatremia (CIH) are limited and mostly focus on the initial administration. This study aimed to assess the overall incidence of CIH and identify significant predictive factors.
methodsWe conducted a single-center, retrospective cohort study of patients who received intravenous cisplatin at Juntendo University Hospital between 2018 and 2020. The occurrence and severity of CIH were assessed across all administrations. Predictive factors were analyzed using multiple logistic regression and generalized linear mixed models.
resultsAmong 706 patients, 340 (48.2%) experienced CIH during the study period, with 103 (14.6%) developing Grade 3 or higher severity. Across 1939 total cisplatin administrations, CIH occurred in 585 (30.2%) cases, including 135 (7.0%) with Grade ≥ 3 severity. CIH was most common at first administration (38.8%), with severe cases occurring in 11.9%. Generalized linear mixed models results that the significant prognostic factors for cisplatin-induced Hyponatremia were age (OR: 1.41, p < 0.001), last cisplatin dose (OR: 1.74, p < 0.001), serum albumin (OR: 0.65, p < 0.001), serum sodium (OR: 0.35, p < 0.001), WBC (OR: 1.26, p = 0.01), and concomitant 5-FU administration (OR: 3.91, p < 0.001).
conclusionsCIH is a frequent and potentially serious complication of cisplatin therapy. Older age, high-dose cisplatin, hypoalbuminemia, hyponatremia, leukocytosis, and 5-FU co-administration significantly increase the risk. These findings highlight the importance of proactive monitoring and management strategies to mitigate CIH risk.
Indexed as
Identifiers
42496909What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.